A randomized, double-blind, placebo-controlled, parallel group study to determine the efficacy, the duration of action, and safety of latanoprost in patients with Menière’s disease

Registry ID

EUCTR2013-002261-18

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Synphora AB

Start date

2013-08-21

Completion date

2016-05-23

Last update

2026-08-16

Conditions

• Menière´s disease

Summary

The primary objective is to determine the efficacy and duration of action of latanoprost as treatment of Menière’s disease

Locations

• , , Sweden

View on source registry